DPTIP

Research use only, not for human use.

DPTIP is an effective inhibitor of neutral sphingomyelinase 2 with an IC50 value of 30 nM.

DPTIP is an effective inhibitor of neutral sphingomyelinase 2 with an IC50 value of 30 nM.(In Vitro):DPTIP (30 μM) decreases exosome release by 50% in astrocytes. DPTIP(0.03-30 μM) dose-dependently blocks EV secretion.(In Vivo):In mice, DPTIP potently (10 mg/kg; i.p.) inhibits IL-1β-induced astrocyte-derived EV release. Brain concentrations of DPTIP are above its IC50 for neutral sphingomyelinase 2 inhibition for at least 4 h after the administration of DPTIP.

DPTIP blocks EV secretion in a dose dependent manner (0.03-30 μM), and at 30 μM, this compound could decrease exosome release by 50% in astrocytes.

DPTIP potently (10?mg/kg IP) inhibits IL-1β-induced astrocyte-derived EV release. Animal Model:Mice.Dosage:10?mg/kg.Administration:IP 0.5?h prior to IL-1β striatal injection.Result:Brain concentrations of DPTIP are above its IC50 for nSMase2 inhibition for at least 4?h after compound administration.The number of astrocyte-derived EVs was reduced by 51?±?13% 2?h post IL-1β administration.

——

Metabolic Enzyme/Protease

Phospholipase

——

——

——

351353-48-5

378.44

C21H18N2O3S

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (660.61 mM)

OC=1C(OC)=CC(=CC1OC)C2=NC(C=3C=CC=CC3)=C(N2)C=4SC=CC4

——

(-20℃)

With Ice Pack

≥ 2 years